16 completed, 7 unknown, 6 recruiting, 3 active not recruiting. 11 Phase 2, 8 Not applicable, 8 Phase 1, 4 Phase 3, 1 Early Phase 1.
Follow Multiple Sclerosis, Secondary Progressive: new trials by email Literature Review of Multiple Sclerosis, Secondary Progressive trials Research Report on Multiple Sclerosis, Secondary Progressive
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Allogeneic Hematopoietic Cell Transplantation for Primary Progressive Multiple Sclerosis Orca-Q, myeloablative regimen - Primary Progressive Multiple Sclerosis, Multiple Sclerosis | Phase 1 | Not yet recruiting | Stanford University | 10 | 2025-03-01 | 2025-03-28 |
| Effects of Acute Intermittent Hypoxia on Neuroplasticity in MS Acute Intermittent Hypoxia, Sham Acute Intermittent Hypoxia - Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting | Not applicable | Recruiting | Shirley Ryan AbilityLab | 22 | 2025-02-01 | 2026-02-23 |
| Clinnova-MS: A Prospective Cohort Study of Patients With Multiple Sclerosis (Switzerland) All participants will be asked to provide data and samples for collection and analysis. - Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting | Recruiting | University Hospital, Basel, Switzerland | 100 | 2024-12-10 | 2025-12-26 | |
| PET Study of PIPE-791 in Healthy Volunteers and Volunteers With PrMS and IPF PIPE-791 - Idiopathic Pulmonary Fibrosis (IPF), Idiopathic Pulmonary Fibrosis | Phase 1 | Completed | Contineum Therapeutics | 16 | 2024-12-09 | 2025-08-06 |
| The Synergistic Effects of AIH and FES in Persons With MS Acute Intermittent Hypoxia, Neuromuscular Electrical Stimulation - Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting | Not applicable | Active not recruiting | Shirley Ryan AbilityLab | 40 | 2024-11-01 | 2026-02-23 |
| KYSA-7: A Study of Anti-CD19 CAR T-Cell Therapy, in Subjects With Refractory Primary and Secondary Progressive Multiple Sclerosis KYV-101, Standard lymphodepletion regimen, Anti-CD20 mAB - Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive | Phase 2 | Active not recruiting | Kyverna Therapeutics | 120 | 2024-09-20 | 2025-01-13 |
| Development of Camera Based Gait Quality Measure for Persons With Multiple Sclerosis Camera Based Kinematic Analysis - Multiple Sclerosis, Multiple Sclerosis, Secondary Progressive | Unknown | Shirley Ryan AbilityLab | 40 | 2024-07-01 | 2024-07-24 | |
| Intermittent Hypoxia in Persons With Multiple Sclerosis Acute Intermittent Hypoxia, Sham-Acute Intermittent Hypoxia - Multiple Sclerosis, Multiple Sclerosis-Relapsing-Remitting | Not applicable | Recruiting | Shirley Ryan AbilityLab | 21 | 2024-04-30 | 2026-03-20 |
| A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell ( CAR-T) Therapy in Subjects With Non-relapsing and Progressive Forms of Multiple Sclerosis KYV-101 anti-CD19 CAR-T cell therapy, Standard lymphodepletion regimen - Multiple Sclerosis, Multiple Sclerosis, Primary Progressive | Phase 1 | Recruiting | Stanford University | 12 | 2024-04-10 | 2026-02-27 |
| The Effects of In-phase Bilateral Exercise in People with Progressive Multiple Sclerosis In-phase Bilateral Exercise, Conservative exercises - Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive | Not applicable | Completed | Cyprus University of Technology | 20 | 2023-10-02 | 2024-09-19 |
| An Observational Biomarker Study in Multiple Sclerosis (MS) Patients Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Primary Progressive | Completed | LAPIX Therapeutics Inc. | 137 | 2023-03-28 | 2024-06-11 | |
| Cladribine vs Placebo for Non-active Progressive Multiple Sclerosis (CLASP-MS). Cladribine Subcutaneous Injection, 0.9% Chloride Injection Sodium - Multiple Sclerosis, Secondary Progressive, Multiple Sclerosis | Phase 2 / Phase 3 | Recruiting | Institute of Psychiatry and Neurology, Warsaw | 188 | 2022-10-03 | 2023-07-28 |
| MUSCLE - Nordic Walking in MUltiple SCLErosis Nordic Walking (NWG), Free Walking (FWG), Health Education (HEG) - Multiple Sclerosis, Chronic Progressive, Multiple Sclerosis | Not applicable | Unknown | Leonardo A. Peyré-Tartaruga | 60 | 2022-08-02 | 2022-05-23 |
| Exercise Effects in Multiple Sclerosis Exercise Group 1, Exercise Group 2, Exercise Group 3 - Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Relapsing-Remitting | Not applicable | Unknown | University of Regina | 69 | 2022-06-15 | 2024-02-15 |
| Novel Imaging Markers in SPMS Ferumoxytol infusion, Gadoteridol, MRI Brain and Cervical Spine - Secondary Progressive Multiple Sclerosis, Multiple Sclerosis, Secondary Progressive | Early Phase 1 | Completed | University of Utah | 11 | 2022-06-01 | 2026-08-13 |
| Safety and Efficacy of Extracorporeal Photopheresis (ECP) in the Treatment of Multiple Sclerosis Extracorporeal Photopheresis, MS standard of care - Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting | Phase 1 / Phase 2 | Completed | Abu Dhabi Stem Cells Center | 15 | 2022-03-26 | 2026-05-07 |
| Neuroprotection With N-acetyl Cysteine for Patients With Progressive Multiple Sclerosis N-acetyl cysteine, Placebo - Multiple Sclerosis, Multiple Sclerosis, Primary Progressive | Phase 2 | Active not recruiting | Emmanuelle Waubant, MD PhD | 98 | 2022-02-16 | 2026-03-11 |
| MS-ResearchBiomarkerS Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting | Recruiting | Cedars-Sinai Medical Center | 1000 | 2021-11-11 | 2024-02-06 | |
| Motor Asymmetry in Progressive Multiple Sclerosis Patients Magnetic Resonance Imaging, Neurological examination, Multiple Sclerosis Functional Composite - Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive | Completed | Rennes University Hospital | 46 | 2021-11-03 | 2026-03-19 | |
| Hydroxychloroquine and Indapamide in SPMS Hydroxychloroquine Pill, Indapamide Pill - Multiple Sclerosis, Secondary Progressive | Phase 2 | Unknown | University of Calgary | 35 | 2021-10-01 | 2022-05-18 |
Showing 20 of 35. Sign in to see all of them.
Multiple Sclerosis, Chronic Progressive (35) · Multiple Sclerosis (22) · Multiple Sclerosis, Relapsing-Remitting (18) · Autoimmune Diseases (3) · Hypoxia (3) · Autoimmune Diseases of the Nervous System (2) · Nervous System Diseases (2) · Demyelinating Autoimmune Diseases, CNS (1) · Demyelinating Diseases (1) · Disease Progression (1) · Idiopathic Pulmonary Fibrosis (1) · Immune System Diseases (1) · Mobility Limitation (1) · Motor Activity (1) · Movement Disorders (1)
Chronic Disease (35) · Disease Attributes (35) · Pathological Conditions, Signs and Symptoms (35) · Demyelinating Autoimmune Diseases, CNS (34) · Demyelinating Diseases (34) · Immune System Diseases (34) · Pathologic Processes (34) · Autoimmune Diseases of the Nervous System (33) · Nervous System Diseases (33) · Autoimmune Diseases (32) · Multiple Sclerosis (13) · Signs and Symptoms (4) · Signs and Symptoms, Respiratory (3) · Central Nervous System Diseases (2) · Behavior (1)
Insemination, Artificial, Homologous (3) · Dimethyl Fumarate (2) · Acetylcysteine (1) · Bendamustine Hydrochloride (1) · Busulfan (1) · Domperidone (1) · Ferrosoferric Oxide (1) · Fluorodeoxyglucose F18 (1) · Glatiramer Acetate (1) · Hydroxychloroquine (1) · Indapamide (1) · Insulin (1) · Interferons (1) · MBP-8298 (1) · Magnetic Resonance Spectroscopy (1)
Shirley Ryan AbilityLab (4) · Johns Hopkins University (2) · Stanford University (2) · University of Calgary (2) · AB Science (1) · Abu Dhabi Stem Cells Center (1) · Amsterdam UMC, location VUmc (1) · Assistance Publique - Hôpitaux de Paris (1) · BioMS Technology Corp. (1) · Biogen (1) · Cedars-Sinai Medical Center (1) · Contineum Therapeutics (1) · Cyprus University of Technology (1) · Danish Research Centre for Magnetic Resonance (1) · Emmanuelle Waubant, MD PhD (1)
United States (16) · Canada (3) · France (3) · Poland (3) · Germany (2) · Netherlands (2) · Belgium (1) · Brazil (1) · Bulgaria (1) · Chile (1) · Cyprus (1) · Czechia (1) · Denmark (1) · Greece (1) · Japan (1)
Scott Newsome, DO (2) · Anne Kerbrat, MD (1) · Brooke Guerrero, MD (1) · Bruno Stankoff (1) · Cameron Mang, PhD (1) · Clyde E Markowitz, MD (1) · Cristina Granziera, Prof. (1) · Dimitris Sokratous (1) · Ellen Mowry, MD, MCR (1) · Friedemann Paul (1) · Hartwig R Siebner, Professor (1) · Iwona Kurkowska-Jastrzebska, MD, PhD (1) · J. Killestein, prof. dr. (1) · Jaye Thompson, PhD (1) · Jeffrey Dunn, MD (1)
PMID 12324550, PMID 12525714, PMID 12527959, PMID 20023002, PMID 20156050, PMID 21056491, PMID 23552330, PMID 23869824, PMID 24262162, PMID 27017543, PMID 28017241, PMID 28178885, PMID 28915856, PMID 30157388, PMID 30844920, PMID 32380977, PMID 32911307, PMID 33054533, PMID 34038379, PMID 34123427, PMID 34197674, PMID 34780079, PMID 34803726, PMID 35084560, PMID 35190477, PMID 36182028, PMID 36229188, PMID 37291448, PMID 37537928, PMID 38129896, PMID 38224478, PMID 39217272, PMID 39652340, PMID 41342004, PMID 41342942, PMID 41509523, PMID 41841206, PMID 6685237
2014 (1), 2023 (1), R21HD108587 (1), U01NS082329 (1), UL1TR002538 (1)